SAFETY Meeting Minutes
Biosafety Committee
5/26/2026 1:00 PM
Zoom

MEETING TIME RECORDS

Meeting start time: 1:02PM
Meeting end time: 1:33PM

VOTING MEMBER ATTENDANCE

Name	Substituting For	Attendance
Mark Klang		Present
Andy Koff		Present
Xiuyan Wang		Absent
Prasad Adusumilli		Present
Justin Laracy		Present
Lauren Wood		Absent
Paul Zel		Present
Philip Hauck		Absent
Hillary Frommer		Present
Zainab Shahid		Absent
Geoffrey Ku		Present
Rui Gardner		Absent
Marc Kramer		Absent
Sham Mailankody		Present
Paul O'Brien		Present
Andrea Ventura		Absent
Christine Iacobuzio-Donahue		Present
Shuchi Agarwal		Present

NON-VOTING ATTENDEES/GUESTS

Asmita Kumar
Rivka Schwarcz
Gary Martin
Richard Ellis

QUORUM INFORMATION

Number of SAFETY members on the roster: 18
Number required for quorum: 10

All members present by teleconference received all pertinent material before the meeting and were able to actively and equally participate in all discussions.

ATTENDANCE STATUS AND VOTING KEY	
ABSTAIN:	Present for the vote, but not voting "For" or "Against."
ABSENT:	Absent for discussion and voting for reasons other than a conflicting interest.
RECUSED:	Absent from the meeting during discussion and voting because of a conflicting interest.
SUBSTITUTION:	When regular members and their alternate(s) are listed in the ATTENDANCE table above and an alternate member substitutes for the regular member this identifies the name of the alternate to indicate which individual is serving as the voting member for this vote. May be deleted if there are no substitutions.

GUEST NAMES
Dina Abdurahman
Mashtura Tashnuva
Gabrielle Wirkus

DISCUSSION

The Minutes from the February, March Ad hoc, and March meetings were approved. The IBC discussed a balanced approach to managing proprietary information in the meeting minutes, ensuring transparency while protecting patient privacy and sponsor confidentiality.

REVIEW OF CLINICAL SUBMISSIONS

Initial Protocol

1. **Review of PROTO202600013**

Title:	MED26-075
Investigator:	Hamza Hashmi
Submission ID	PROTO202600013

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the initial review for a single-arm, open-label, multi-center, Phase Ib/II clinical study designed to evaluate the safety and efficacy of AZD0120, a chimeric antigen receptor T cell infusion in participants with relapsed/refractory multiple myeloma (RRMM) who have received at least 3 prior lines of MM therapy including a protease inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. The Reveiwer did not have any concerns and recommended approval. The Committee voted to approve the initial protocol.
e. **Applicable section of NIH Guidelines:** Section III-C-1
f. **Containment level:** BSL-2
g. **Votes:**
For: 10

Against: 0
Recused: 2
Absent: 6
Abstained: 0

Amendment/CR

2. **Review of SAF04010**

Title:	Amendment/CR for PROTO202400007
Investigator:	Sridevi Rajeeve
Submission ID	SAF04010

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the annual renewal and amendment for a phase Ib/II clinical trial designed to evaluate the safety, tolerability, and efficacy of the study agent, GC012F, which is composed of autologous T cells genetically engineered using a self-inactivating (SIN), replication-deficient recombinant lentiviral vector to express Chimeric Antigen Receptors (CARs) targeting CD19 and B-cell maturation antigen (BCMA) in adult subjects with relapsed/refractory multiple myeloma after receiving at least three prior treatment lines of therapy. No changes, accidents, or loss of containment were reported. The purpose of the amendment was to update personnel and protocol documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual renewal.
e. **Applicable section of NIH Guidelines:** Section III-C-1
f. **Containment level:** BSL-2
g. **Votes:**
For: 10
Against: 0
Recused: 2
Absent: 6
Abstained: 0

Amendment/CR

3. **Review of SAF04024**

Title:	Amendment/CR for PROTO202400006
Investigator:	Maria Palomba
Submission ID	SAF04024

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None

d. **Comments:** This is the annual renewal and amendment for a phase 1 study of axicabtagene ciloleucel in relapsed or refractory HIV-associated aggressive B-cell non-Hodgkin lymphoma (B-NHL). The primary objective is to demonstrate safety and feasibility of axicabtagene ciloleucel for relapsed/refractory HIV-associated aggressive B-NHL in participants with well-controlled HIV. No accidents or loss of containment were reported. The purpose of the amendment was to update personnel, funding, and protocol documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual renewal.

e. **Applicable section of NIH Guidelines:** Section III-C-1

f. **Containment level:** BSL-2

g. **Votes:**

For:	10
Against:	0
Recused:	2
Absent:	6
Abstained:	0

Amendment/CR

4. **Review of SAF03977**

Title:	Amendment/CR for PROTO202500002
Investigator:	Jae Park
Submission ID	SAF03977

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the annual renewal and amendment for a phase 1/2, open-label study to evaluate the safety and efficacy of autologous CD19-specific chimeric antigen receptor T cells (CABA-201) in subjects with active Idiopathic Inflammatory Myopathy (IMM) or Active Juvenile Idiopathic Inflammatory Myopathy (JIMM). This study will evaluate the safety and tolerability of CABA-201 in subjects with active IIM and JIIM, evaluate the effects of CABA-201 on white blood cell and B cell counts, evaluate CABA-201 manufacturing success rates, characterize manufacturing process using subject cells, evaluate CABA-201 persistence and kinetics after infusion, evaluate the effects of CABA-201 on IIM and JIIM disease activity, evaluate the effect of CABA-201 on steroid use and other IIM/JIIM-related therapy and evaluate the effects of CABA-201 on PROS/QOL, IIM disease flares and on drug-free response. No accidents or loss of containment were reported. The purpose of the amendment was to update personnel. The Reviewer did not have any concerns and recommended approval.

e. **Applicable section of NIH Guidelines:** Section III-C-1

f. **Containment level:** BSL-2

g. **Votes:**

For: 10
Against: 0
Recused: 2
Absent: 6
Abstained: 0

Amendment/CR

5. **Review of SAF04031**

Title:	Amendment/CR for PROTO202000027
Investigator:	Urvi Shah
Submission ID	SAF04031

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the annual renewal and amendment for a phase 3 open-label, multicenter study trial to compare the efficacy of JNJ-68284528, an autologous chimeric antigen receptor T cell therapy that targets B-cell maturation antigen (BCMA) with standard therapy in subjects with relapsed and lenalidomide-refractory multiple myeloma (MM). No changes, accidents, or loss of containment were reported. The purpose of the amendment was to update the PI and protocol documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual renewal.
e. **Applicable section of NIH Guidelines:** Section III-C-1
f. **Containment level:** BSL-2
g. **Votes:**
For: 11
Against: 0
Recused: 1
Absent: 6
Abstained: 0

Amendment/CR

6. **Review of SAF04035**

Title:	Amendment/CR for PROTO202500007
Investigator:	Jonathan Coleman
Submission ID	SAF04035

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the annual renewal and amendment for a phase 1/2, multi-center, open-label, single-arm, repeat dose trial to investigate the safety and efficacy of

nadofaragene firadenovec, a replication-deficient recombinant adenovirus, instilled into the renal pelvis in patients with low-grade upper tract urothelial carcinoma (LG-UTUC). No changes, accidents, or loss of containment were reported. The purpose of the amendment was to update protocol documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual review.

e. **Applicable section of NIH Guidelines:** Section III-C-1

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Amendment/CR

7. **Review of SAF04021**

Title:	Amendment/CR for PROTO202100004
Investigator:	Ritesh Kotecha
Submission ID	SAF04021

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the annual renewal and amendment for a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, efficacy, cellular kinetics and immunogenicity of ALLO-316 (an allogeneic T cell receptor alpha constant (TRAC)/cluster of differentiation (CD)52-knockout (KO) allogeneic chimeric antigen receptor (CAR) T cell product) in adult subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC). In addition, safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALLO-647 in combination with Fludarbine/Cyclophosphamide will also be assessed. The aim of the study is to evaluate the safety of ALLO-316, define its maximum tolerated dose (MTD) and/or establish the recommended phase 2 dose (RP2D) of ALLO-316. No accidents or loss of of containment were reported. The purpose of the amendment was to update personnel and protocol documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual renewal.

e. **Applicable section of NIH Guidelines:** Section III-C-1

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0

Absent: 6
Abstained: 0

Amendment/CR

8. **Review of SAF04023**

Title:	Amendment/CR for PROTO202400008
Investigator:	Ritesh Kotecha
Submission ID	SAF04023

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the annual renewal and amendment for a first-in-human, single-arm, open-label, multicenter Phase I/II trial designed to assess the safety, tolerability, and efficacy of AB-2100, an autologous T cell product engineered with a CRISPR/Cas9 system to express an inducible Chimeric Antigen Receptor (CAR) against carbonic anhydrase 9 for the treatment of participants with advanced or metastatic clear-cell renal cell carcinoma. AB-2100 is also engineered to constitutively express a pathway activator for Signal Transducer and Activator of Transcription 3 (STAT3) and short hairpin microRNAs against FS7-associated surface antigen and Transforming Growth Factor Beta (TGF-β) receptor type 2 for enhanced CAR-T function and expansion. No accidents or loss of containment were reported. The purpose of the amendment was to update personnel and protocol documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual renewal.
e. **Applicable section of NIH Guidelines:** Section III-C-1
f. **Containment level:** BSL-2
g. **Votes:**
For: 12
Against: 0
Recused: 0
Absent: 6
Abstained: 0

Continuing Review

9. **Review of SAF04025**

Title:	Continuing Review for PROTO201900025
Investigator:	Vinod Balachandran
Submission ID	SAF04025

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None

d. **Comments:** This is the annual renewal for a phase I trial to determine the safety of sequential administration of atezolizumab and RO7198457 (an RNA-based individualized neoantigen specific therapy, iNeST), followed by standard of care mFOLFIRINOX. No changes, accidents, or loss of containment were reported. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the annual renewal.

e. **Applicable section of NIH Guidelines:** Section III-C-1

f. **Containment level:** BSL-1

g. **Votes:**

For:	11
Against:	0
Recused:	1
Absent:	6
Abstained:	0

Continuing Review

10. **Review of SAF04037**

Title:	Continuing Review for PROTO202300007
Investigator:	Cameron Brennan
Submission ID	SAF04037

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments**: This is the annual renewal for a Phase I trial to test if rQNestin34.5v.2, a genetically engineered HSV-1 virus, is safe to use in humans and if it is effective in treating malignant glioma. Initially a lower dose level will be tested. If this is well tolerated without significant side effects, a higher dose level will then be tested in a second group of participants. No changes, accidents, or loss of containment were reported. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the annual renewal.

e. **Applicable section of NIH Guidelines:** Section III-C-1

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Continuing Review

11. **Review of SAF03985**

Title:	Continuing Review for PROTO202300014
Investigator:	Fiorella Iglesias Cardenas
Submission ID	SAF03985

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the annual renewal for a phase 1/2 study of genetically engineered afamitresgene autoleucel (an autologous T-cell product) in HLA-A*02:01, HLA-A*02:02, HLA-A*02:03, or HLA-A*02:06 allele subjects with MAGE-A4 expressing locally advanced inoperable or metastatic cancer of the following types: synovial sarcoma (SS), malignant peripheral nerve sheath tumor (MPNST), neuroblastoma (NB), or osteosarcoma (OS). The primary objective of this study is to evaluate the safety and tolerability of afamitresgene autoleucel. Secondary objectives include to evaluate the efficacy of afamitresgene autoleucel in this patient population, to develop and validate an in vitro diagnostic (IVD) assay for the screening of tumor antigen expression for regulatory approval, and to characterize the in vivo cellular pharmacokinetics (PK) profile of afamitresgene autoleucel. No accidents or loss of containment were reported. Changes to personnel were made via an amendment. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the annual renewal.

   Applicable section of NIH Guidelines: Section III-C-1
e. **Containment level:** BSL-2
f. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Amendment

12. **Review of SAF03981**

Title:	Amendment for PROTO202300014
Investigator:	Fiorella Iglesias Cardenas
Submission ID	SAF03981

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is an amendment to update personnel and protocol documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment.
e. **Applicable section of NIH Guidelines:** Section III-C-1
f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

REVIEW OF LABORATORY SUBMISSIONS

Triennial Protocol

13. **Review of LAB202600028**

Title:	Cristina Antonescu lab
Investigator:	Cristina Antonescu
Submission ID	LAB202600028

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the triennial review for the Antonescu lab. The lab studies gene expression profiling of epithelioid hemangioendothelioma to unravel potential therapeutic targets. The Reviewer requested clarification about the location of the work. This issue was addressed, and the Reviewer had no further concerns and recommended approval. The Committee voted to approve the triennial review.

e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-3-b

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Triennial Protocol

14. **Review of LAB202600026**

Title:	RNAi Core Facility (Ralph Garippa)
Investigator:	Ralph Garippa
Submission ID	LAB202600026

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the triennial renewal for the RNAi Core Facility. This facility supports MSKCC investigators in their research programs with two RNA-guided

technologies: RNA Interference (RNAi) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). The RNAi Core supplies the investigators with various RNAi and CRISPR reagents to study individual genes, dissect signaling pathways, and identify potential drug targets. The RNAi Core also provides high-throughput screening (HTS) and High Content Screening (HCS) services to the MSKCC research community. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.

e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-3-b

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Triennial Protocol

15. **Review of LAB202600030**

Title:	Darren Veach Lab
Investigator:	Darren Veach
Submission ID	LAB202600030

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the triennial renewal for the Veach lab. The overall objectives of the Veach Lab / Nuclear Medicine Research Laboratory are the identification, synthesis, and empirical evaluation of radiotracers for the non-invasive detection, localization, and metabolic characterization of human tumors and their microenvironment. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.

e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-3-b

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Triennial Protocol

16. **Review of LAB202600027**

Title:	Alexander Gitlin Lab
Investigator:	Alexander Gitlin
Submission ID	LAB202600027

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the triennial renewal for the Gitlin lab. This lab studies how inflammatory cell signaling controls the nature and magnitude of inflammation under physiological and disease conditions. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.
e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-1-a, III-D-3-b
f. **Containment level:** BSL-2
g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Triennial Protocol

17. **Review of LAB202600024**

Title:	Meng-Fu Tsou lab
Investigator:	Meng-Fu Tsou
Submission ID	LAB202600024

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the triennial renewal for the Tsou lab. The goal of their research is to understand the biogenesis of centrioles, centrosomes, and primary cilia, and how these processes affect mammalian cell physiology. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.
e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-1-a, III-D-3-b
f. **Containment level:** BSL-2
g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6

Abstained: 0

Triennial Protocol

18. **Review of LAB202600029**

Title:	Vinod Balachandran lab
Investigator:	Vinod Balachandran
Submission ID	LAB202600029

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the triennial renewal for the Balachandran lab. The major goals of their experiments are to discover new ways to stimulate the immune system to treat pancreatic cancer. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.
e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-1-a, III-D-3-b
f. **Containment level:** BSL-2
g. **Votes:**

For: 12
Against: 0
Recused: 0
Absent: 6
Abstained: 0

Triennial Protocol

19. **Review of LAB202600031**

Title:	Hans Wendel Lab
Investigator:	Hans Wendel
Submission ID	LAB202600031

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the triennial renewal for the Wendel lab. The Wendel lab focused on the genetics of cancer and the development of new therapies. The research is geared to understand how genetic lesions incurred during tumor evolution impact responses to conventional therapy and if they provide opportunities for new therapies. The Reviewer requested clarification about protective equipment and transportation procedures. These issues were addressed, and the Committee voted to approve the triennial renewal.
e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-3-a, III-D-3-b

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Amendment/CR

20. **Review of SAF04028**

Title:	Amendment/CR for LAB202500035
Investigator:	Michael Berger
Submission ID	SAF04028

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the annual renewal and amendment for the Berger lab. They are developing and applying methods of profiling individual tumor specimens for somatic base mutations and other genomic alterations that may influence response to therapy. No accidents or loss of containment were reported. Changes to personnel were made via an amendment. The Committee voted to approve the amendment and annual renewal.

e. **Applicable section of NIH Guidelines:** None

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Amendment/CR

21. **Review of SAF04005**

Title:	Amendment/CR for LAB202400006
Investigator:	Xiaolan Zhao
Submission ID	SAF04005

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the annual renewal and amendment for the Zhao lab. They study the mechanisms of chromosomal replication and repair using the baker's yeast as a

model system. No accidents or loss of containment were reported. The purpose of the amendment was to update personnel. The Committee voted to approve the amendment and annual review.

e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-II, III-F-8 Appendix C-III

f. **Containment level:** BSL-1

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Amendment/CR

22. **Review of SAMENDCR202600000009**

Title:	Amendment/CR for LAB202500034
Investigator:	Charles Sawyers
Submission ID	SAMENDCR202600000009

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the annual renewal and amendment for the Sawyers lab. Their laboratory is focused on characterizing signal transduction pathway abnormalities in various cancers with an eye toward translational implications. No changes, accidents, or loss of containment were reported. Changes to personnel were made via an amendment. The Committee voted to approve the amenemdnt and annual renewal.

e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-3-a, III-D-3-b

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Amendment/CR

23. **Review of SAF03980**

Title:	Amendment/CR for LAB202500040
Investigator:	Tobias Hohl
Submission ID	SAF03980

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the annual renewal and amendment for the Hohl lab. Their lab focuses on fungal pathogenesis and immunology, with a primary focus on deciphering the molecular and cellular events required for effective antifungal immunity. No accidents or loss of containment were reported. Changes to personnel were made via amendment. The Committee voted to approve the amendment and annual renewal.
e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-1-a, III-D-3-a, III-D-3-b
f. **Containment level:** BSL-2
g. **Votes:**

For: 12
Against: 0
Recused: 0
Absent: 6
Abstained: 0

Amendment/CR

24. **Review of SAF04007**

Title:	Amendment/CR for LAB202500038
Investigator:	Frederic Geissmann
Submission ID	SAF04007

a. **Determination:** Approved
b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the annual renewal and amendment for the Geissmann lab. Their lab aims to define the development of cells of the mononuclear phagocyte system in vivo and in vitro, and to characterize the contribution of monocyte and macrophages subsets to the inflammatory response in models for the complications of obesity, inflammation, neurodegeneration and cancer and the mechanisms involved by studying human and mouse macrophages. No accidents or loss of containment were reporte. The purpose of the amendment was to update personnel. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual renewal.
e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-3-b
f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Continuing Review

25. **Review of SAF04020**

Title:	Continuing Review for LAB202500027
Investigator:	Ross Levine
Submission ID	SAF04020

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the annual renewal for the Levine lab. The goal of their research lab is to improve the understanding of the molecular basis of leukemia. They perform studies to identify novel disease alleles and then perform characterization of these disease alleles. No accidents or loss of containment were reported. Changes to personnel were indicated. The Committee voted to approve the annual renewal.

e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-1-a, III-D-3-b

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Continuing Review

26. **Review of SAF04018**

Title:	Continuing Review for LAB202500039
Investigator:	Elisa de Stanchina
Submission ID	SAF04018

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the annual review for the Experimental Antitumor Testing Core Facility. The facility provides services to support early discovery of effective antitumor agents and regimens of therapies at Memorial Sloan Kettering Cancer Center. In particular, the facility provides resources, professional and technical

expertise, and advisory services related to the evaluation of agents with potential therapeutic activity. No changes, accidents, or loss of containment were reported. The Committee voted to approve the annual renewal.

e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-D-1-a

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Continuing Review

27. **Review of SAF04040**

Title:	Continuing Review for LAB202400004
Investigator:	Luc Morris
Submission ID	SAF04040

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027

c. **Required modifications:** None

d. **Comments:** This is the annual renewal for the Morris lab. Their laboratory studies genomic and immunological features of head and neck carcinoma. They are interested in validating techniques/protocol related to Immunotherapy treatment. No changes, accidents, or loss of containment were reported. The Committee voted to approve the annual renewal.

e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-1-a, III-D-3-b

f. **Containment level:** BSL-2

g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Continuing Review

28. **Review of CR202600000002**

Title:	Continuing Review for LAB202500008
Investigator:	Stewart Shuman
Submission ID	CR202600000002

a. **Determination:** Approved

b. **Last day of continuing review period:** 5/31/2027
c. **Required modifications:** None
d. **Comments:** This is the annual renewal for the Shuman lab. The goal of research in the Shuman lab is to understand the mechanisms and structures of enzymes that perform and regulate essential nucleic acid transactions. No changes, accidents, or loss of containment were reported. The Committee voted to approve the annual renewal.
e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-II, III-F-8, Appendix C-III
f. **Containment level:** BSL-1
g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Amendment
29. **Review of SAF04043**

Title:	Amendment for LAB202500099
Investigator:	Joseph Sun
Submission ID	SAF04043

a. **Determination:** Approved
b. **Last day of continuing review period:** 11/30/2026
c. **Required modifications:** None
d. **Comments:** This is an amendment to add established Vaccinia models. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment.
e. **Applicable section of NIH Guidelines:** III-D-1-a
f. **Containment level: BSL-2**
g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Amendment
30. **Review of SAF04033**

Title:	Amendment for LAB202500030
Investigator:	Alan Hanash
Submission ID	SAF04033

a. **Determination:** Approved
b. **Last day of continuing review period:** 4/30/2027
c. **Required modifications:** None
d. **Comments:** This is an amendment to add Cholera toxin, AAV constructs, and personnel. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment.
e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I
f. **Containment level:** BSL-1
g. **Votes:**

For: 12
Against: 0
Recused: 0
Absent: 6
Abstained: 0